Corcept Therapeutics
CORT
183 hedge funds and large institutions have $962M invested in Corcept Therapeutics in 2019 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 65 increasing their positions, 65 reducing their positions, and 38 closing their positions.
59% more call options, than puts
Call options by funds: $5.21M | Put options by funds: $3.27M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 65
1.19% less ownership
Funds ownership: 76.31% → 75.12% (-1.2%)
6% less capital invested
Capital invested by funds: $1.03B → $962M (-$66.1M)
12% less funds holding
Funds holding: 208 → 183 (-25)
53% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 38
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$9.57M |
| 2 |
Morgan Stanley
New York
|
+$6.17M |
| 3 |
Renaissance Technologies
New York
|
+$5.94M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
+$5.83M |
| 5 |
MCM
Matarin Capital Management
New York
|
+$5.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$10.1M |
| 2 |
CCM
Consonance Capital Management
New York
|
-$9.63M |
| 3 |
Millennium Management
New York
|
-$4.73M |
| 4 |
Goldman Sachs
New York
|
-$3.74M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$3.69M |
CORT Hedge Fund Activity: Q2 2019 in Review
183 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q2 2019, worth a combined $962M — down 6.4% from $1.03B a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of CORT and 18 opened new positions — a net loss of 20 holders — while 65 trimmed existing stakes and 65 added.
The largest buyer was Citadel Advisors, adding an estimated $9.57M. The largest seller was Federated Hermes, cutting an estimated $10.1M.
- 183 institutional investors held Corcept Therapeutics (CORT) as of Q2 2019, down from 208 in Q1 2019.
- Funds reported $962M of Corcept Therapeutics stock for Q2 2019, down 6.4% quarter-over-quarter.
- 18 funds opened new Corcept Therapeutics positions in Q2 2019 and 38 closed out, a net change of -20 holders.
- The largest Corcept Therapeutics buyer in Q2 2019 was Citadel Advisors, an estimated $9.57M added.
- The largest Corcept Therapeutics seller in Q2 2019 was Federated Hermes, an estimated $10.1M sold.
Based on aggregated 13F filings for Q2 2019.